Opamistomig Biosimilar Bispecific Antibody (PD-L1 × 4-1BB) for Research

Cat No.: GMP-Bios-INN-1316

Anti-PDL1/CD274 therapeutic antibody (Pre-made Opamistomig biosimilar,Bispecific Mixed mAb and scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Opamistomig (development code LBL-024) is a bispecific antibody developed for oncology indications. Further development details are under investigation.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1316-1mg 1mg
GMP-Bios-INN-1316-10mg 10mg
GMP-Bios-INN-1316-100mg 100mg
GMP-Bios-INN-1316-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Opamistomig biosimilar, Bispecific Mixed mAb and scFv, Anti-PDL1/CD274;TNFRSF9/CD137/4-1BB Antibody: Anti-PD-L1/CD274/Programmed cell death 1 ligand 1/PDCD1 ligand 1 therapeutic antibody
INN Name Opamistomig
Target PDL1/CD274;TNFRSF9/CD137/4-1BB
Format Bispecific Mixed mAb and scFv
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G1;na
VD LC Kappa;Lambda
Highest_Clin_Trial (Jan '20) TBC
Est. Status TBC
100% SI Structure None;None
99% SI Structure None;None
95-98% SI Structure None;None
Year Proposed 2025
Year Recommended na
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech TBC